SecBot SecBot
SECBOTREPLAY Home › Report › RDY

RDY · Dr

DR REDDYS LABORATORIES LTD · 6-K filed Jul 22, 2026 at 13:59 ET

At the news

BEARISHIMPACT 6/10

6-K filed Jul 22, 2026 at 13:59 ET

Dr. Reddy's Q1 FY2027 results were sharply below prior year: revenue fell 6% YoY to Rs.80,705M, operating profit collapsed 78% to Rs.3,784M, and EPS dropped 69% to Rs.5.32. The US generics business was the primary drag, with North America revenue down 35% (41% in USD) due to price erosion and volume declines. Gross margin contracted 10.4pp to 46.5%, further pressured by a Rs.2,397M semaglutide inventory write-down. Growth in India (+17%), Emerging Markets (+31%), and Russia (+28%) partially offset the US decline but could not prevent a 69% profit plunge.

  • Revenue decreased 6% YoY to Rs.80,705M (Q1 FY2026: Rs.85,452M)
  • North America (US+Canada) revenue fell 35% to Rs.22,048M; in USD terms down 41%
  • Gross profit margin collapsed from 56.9% to 46.5%
  • Operating profit (results from operating activities) down 78% to Rs.3,784M

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access